USUHS

ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome

Retrieved on: 
목요일, 3월 28, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Radiation, Acute radiation syndrome, Attack, ARS, Inflammation, Education, Chronic obstructive pulmonary disease, RNCP, USUHS, Virus, IND, European Medicines Agency, Outline of health sciences, Nausea, Accident, Hypoxia (medical), NIAID, Defense Threat Reduction Agency, AFRRI, HIE, Vaccine, Collection, Vomiting, Food, FDA, Defense, Infection, Peptide, Pharmaceutical industry

“We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.

Key Points: 
  • “We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.
  • AFRRI is unique and powerful radiobiological research institute, with six decades of active, robust, and outstanding support to the U.S. Department of Defense through research, reach-back, and education.
  • It is the only U. S. Department of Defense medical R&D facility dedicated solely to nuclear and radiological defense.
  • ReAlta Life Sciences, Inc. is a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life threatening acute inflammatory and rare diseases.

CCRM FERTILITY WELCOMES REGIONAL DIRECTOR OF CLINICAL REPRODUCTIVE GENETICS, DR. JASMINE ALY, TO JERSEY CITY TEAM

Retrieved on: 
수요일, 3월 27, 2024
ART, WRNMMC, Obstetrics, PCOS, Gynaecology, Obesity, Polycystic disease, Reproductive Sciences, Science, NHGRI, Genetic distance, FACOG, Genetics, COVID-19, Patient, Empathy, Medical genetics, Cooper University Hospital, Research, African Americans, USUHS, Fibroid, Reproduction, Assisted reproductive technology, IRMS, NIH, Polycystic ovary syndrome, Outline of health sciences, Reproductive endocrinology and infertility, Publication, Fertility, REI, Birth control

JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey. Dr. Aly holds the rare distinction of being a triple-specialized physician as an Obstetrician-Gynecologist, Reproductive Endocrinologist, and Medical Geneticist.

Key Points: 
  • JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey.
  • As Regional Director of Clinical Reproductive Genetics, Dr. Aly will bring her expertise to the CCRM Fertility team and aims to leverage her comprehensive fellowship training in genetics to further advance the field and better serve patients.
  • As an esteemed reproductive endocrinologist, she will utilize cutting-edge  technology and innovative scientific techniques to ensure patient success rates continue to rise.
  • "Dr. Aly's expertise in genetics is an invaluable attribute that will redefine care at CCRM | IRMS," notes CCRM Fertility CEO, Bob LaGalia.

Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Retrieved on: 
수요일, 2월 28, 2024
Infection, Therapy, Bangladesh Technical Education Board, Parity, AFRRI, USUHS, Cocaine, Medicine, NIAID, NIH, Bar-Ilan University, PLUR, World War II, FDA, PLX, Partnership, 3D, Food, Ageing, GMP, Hope, BIRAD, Plural, Meat, Risk, Outline of health sciences, CDMO, Climate, Climate change, Health, Water, Food and Drug Administration, Coffee, Knowledge, Agriculture, Food security, Negotiation, Good manufacturing practice, Pharmaceutical industry

Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.

Key Points: 
  • Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.
  • We also estimate that our innovative new production process will reduce the amount of growing area by 95%, potentially preventing deforestation.
  • By creating novel cell-based products both independently and through partnerships, Pluri is showing what’s possible when we all work together.
  • As such, our transformative technology is not only creating long-term value for our shareholders; it’s also making the world a better place.

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

Retrieved on: 
화요일, 7월 11, 2023
Radiation, Depression, War, ARS, U.S. Department of Defense Strategy for Operating in Cyberspace, Marketing, Drug discovery, Survival, Uniformed Services University of the Health Sciences, Bone marrow, Power plant engineering, Infection, Pluri Inc., Cell, Plural, Bangladesh Technical Education Board, PLUR, Animal, Anemia, AFRRI, TASE, Outline of health sciences, USUHS, Orphan, NIAID, FDA, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Thrombocytopenia, NIH, Radiation exposure, Food, Medical imaging, Pharmaceutical industry, Medical device

The work specified by the contract is based on communications with the FDA and will enable Pluri to make significant progress toward marketing approval for PLX-R18.

Key Points: 
  • The work specified by the contract is based on communications with the FDA and will enable Pluri to make significant progress toward marketing approval for PLX-R18.
  • PLX-R18 is developed with the intention of being eligible for purchase by the U.S. Strategic National Stockpile as a medical countermeasure for exposure to nuclear radiation, following FDA approval.
  • H-ARS is a deadly disease that can result from nuclear disasters and radiation exposure.
  • Additionally, PLX-R18 was tested in humans with incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT) and was well tolerated with a favorable safety profile.

Freedom Biosciences Appoints Dr. David Hough as Chief Medical Officer

Retrieved on: 
수요일, 11월 16, 2022
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Geriatric psychiatry, Walter Reed Hospital, Yale University, Outline of health sciences, USUHS, Johnson & Johnson, Uniformed Services University of the Health Sciences, Walter Reed Army Institute of Research, Pharmacology, INVEGA, Mental health, Neurology, Development, Esketamine, Therapy, American Board of Commissioners for Foreign Missions, United States Air Force Scientific Advisory Board, Faculty, Addiction, Army, American Board of Psychiatry and Neurology, Ketamine, MD, Publication, Patient, Pharmaceutical industry, Psychiatry, Research

Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelics-based therapeutics, today announced the appointment of David Hough, MD, as Chief Medical Officer.

Key Points: 
  • Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelics-based therapeutics, today announced the appointment of David Hough, MD, as Chief Medical Officer.
  • In this role, Dr. Hough will oversee Freedom Biosciences clinical development programs as the company advances its pipeline of novel therapeutics for patients with mental health and addiction disorders.
  • Were entering an important phase as we work to advance Freedom Biosciences current lead ketamine-based program, FREE001 , says Dina Burkitbayeva, co-founder and CEO of Freedom Biosciences.
  • Freedom Biosciences is identifying the most efficacious combinations of chemicals and translating those discoveries into promising programs to treat a range of mental health indications, said Dr. David Hough.

Trauma Triage Treatment and Training Decision Support (4TDS)

Retrieved on: 
금요일, 6월 10, 2022
Amos, Science, Navy, Army, Vital signs, Internal bleeding, Research, Transport, Doctor of Philosophy, United States Army Medical Research and Development Command, Joint Base San Antonio, Air force, Artificial intelligence, United States Army Medical Materiel Agency, Outline of health sciences, TCCC, Tactical Combat Casualty Care, Bleeding, Trauma, Probability, Nursing, Solution, Uniformed Services University of the Health Sciences, Biomedical engineering, Systems analysis, FDA, Triage, Training, Poi, Disease, Mortality, Risk, Biotechnology, USUHS, Shock, Diagnosis, MD, Oxygen saturation (medicine), Pacific Northwest National Laboratory, ARA, Engineering, PFC, Health, Mayo Clinic, Clinical professor, JBSA, Medical device

To meet that need, Applied Research Associates, Inc. (ARA), the Mayo Clinic, and Ambient Clinical Analytics developed the Trauma Triage Treatment and Training Decision Support (4TDS) system.

Key Points: 
  • To meet that need, Applied Research Associates, Inc. (ARA), the Mayo Clinic, and Ambient Clinical Analytics developed the Trauma Triage Treatment and Training Decision Support (4TDS) system.
  • Early engagement with experienced military medics and clinicians from all services ensured 4TDS reflects their mental models and work processes.
  • It also built support among potential users should the system transition to operational use.
  • Dr. Herasevich led shock prediction model development and testing with support from ARAs Adam Amos-Binks, PhD.

Steven J. Durning, MD, PhD, Selected as NBME’s 2022 John P. Hubbard Award Recipient

Retrieved on: 
수요일, 4월 6, 2022
Principal, Leadership, Mentorship, Research, German Association for Medical Education, Doctor of Philosophy, CEO, Â, Learning, AMEE, University, Association, Medical education, MBA, USUHS, GLOBE, Physician, Student, Professor, NBME, Pittsburgh, Maastricht University, Pharmaceutical industry, Management, Medicine, Medicine, MD

Philadelphia, PA, April 06, 2022 (GLOBE NEWSWIRE) -- NBME congratulates Steven J. Durning, MD, PhD, as the recipient of its 2022 John P. Hubbard Award in recognition of his extensive contributions to the field of assessment in medical education through leadership, scholarship and service.

Key Points: 
  • Philadelphia, PA, April 06, 2022 (GLOBE NEWSWIRE) -- NBME congratulates Steven J. Durning, MD, PhD, as the recipient of its 2022 John P. Hubbard Award in recognition of his extensive contributions to the field of assessment in medical education through leadership, scholarship and service.
  • Danny Takanishi, Jr., MD, chaired the 2022 Hubbard Award Committee, which is responsible for identifying the recipient following a global nomination process.
  • When Dr. Durning looks to the future, he believes receiving the Hubbard Award will inspire him to increase his contributions.
  • Established in 1983, the Hubbard Award recognizes individuals for their outstanding contributions to the pursuit of assessment excellence within medical education.